MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2025.115717

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2025

Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.

He Yuan, Liu Huiquan, Li Xiaoyang, Wang Jianguo, Wu Haibo, Zhou Hangcheng, Wang Xueru, Cheng Jingjing, Ma Jun, Mei Xinyu, Tian Jieyong, Qian Dong

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

BACKGROUND

Neoadjuvant regimen with a high surgical conversion rate was warranted for initially inoperable patients with locally advanced esophageal squamous cell carcinoma (LAESCC). To evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with camrelizumab and nimotuzumab (NCRCN) followed by surgery in initially inoperable patients with LAESCC.

METHODS

This cohort study was a prospective, one-arm, phase 2 study from December 2021 to December 2023. All patients were supposed to receive neoadjuvant chemoradiotherapy (41.4Gy/23 fractions plus weekly nab-paclitaxel (50 mg/m2) and carboplatin (AUC=2)), camrelizumab (200 mg every three weeks), and nimotuzumab (200 mg every three weeks). The primary endpoint was the 1-year progression-free survival (PFS) rate.

RESULTS

Thirty-five patients were enrolled and underwent neoadjuvant therapy (27 men [77 %]; 8 women [23 %]; median [IQR] age, 67[61-73] years). The surgical conversion rate was 86 % (30/35) with R0 resection rate of 97 % (29/30). The pathological complete response (pCR) rate and major pathologic response (MPR) rate were 37 % (11/30), and 53 % (16/30). After a median observation time of 18.5 months, the total cohort of 1-year PFS and overall survival (OS) rates were 67 % and 80 %, respectively. Those main adverse events of more than grade 3 were lymphopenia (77 %, 27/35), radiation esophagitis (17 %, 6/35), abnormal liver function (11 %, 4/35), and neutropenia (9 %, 3/35). Patients with pCR after neoadjuvant therapy showed increased infiltration of CD8 +T cell and decreased FOXP3 +Treg cell density variation in the tumor microenvironment (P < 0.05). High variation of CD8 +T cell density in tumor was significantly associated with better PFS (HR, 7.69; P = 0.01).

CONCLUSIONS

NCRCN regimen was a promising treatment strategy with a high surgical conversion rate in initially inoperable patients with LAESCC. TRIAL REGISTRATION CLINICALTRIALS.

GOV IDENTIFIER: NCT05355168.

Для цитирования: He Yuan, Liu Huiquan, Li Xiaoyang, Wang Jianguo, Wu Haibo, Zhou Hangcheng, Wang Xueru, Cheng Jingjing, Ma Jun, Mei Xinyu, Tian Jieyong, Qian Dong. Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.. European journal of cancer (Oxford, England : 1990). 2025. DOI: 10.1016/j.ejca.2025.115717.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.